Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma
A Phase I Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma
Sponsor: UConn Health
Terminated
Study recruitment is temporary on hold by the sponsor due to patient recruitment challenges and the ongoing review of the investigational adjuvant.
This PHASE1 trial investigates Ovarian Cancer and is currently terminated or withdrawn. UConn Health leads this study, which shows 13 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2022 — Jul 2024 [monthly]
Terminated PHASE1
Status: Suspended → Terminated
-
Feb 2022 — Dec 2022 [monthly]
Suspended PHASE1
-
Dec 2021 — Feb 2022 [monthly]
Suspended PHASE1
▶ Show 8 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Suspended PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Jan 2020 — Nov 2020 [monthly]
Recruiting PHASE1
-
Sep 2018 — Jan 2020 [monthly]
Recruiting PHASE1
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE1
-
May 2017 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — May 2017 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- UConn Health
For direct contact, visit the study record on ClinicalTrials.gov .